- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Granules India posts marginal rise in Q3 profit
Bengaluru: Drug maker Granules India reported a marginal rise in third-quarter profit, helped by easing raw material costs.
Granules has seen slowing profit growth since the third quarter of 2022. It reported a fall in profit for the past two quarters as it grappled with soaring costs.
The company reported a 0.6% climb in expenses for the third quarter, helped by a 7% fall in raw material costs. In contrast, expenses ranged between 9% and 17% in the last four quarters.
This resulted in a flat profit margin year-on-year at 11%.
Revenue rose 1% to 11.56 billion rupees, with the fixed dosages segment contributing 66% to the total.
Read also: Granules India subsidiary bags USFDA nod for Sildenafil for Oral Suspension
Granules, which focuses on making active pharmaceutical ingredients (API), holds 30% of the global market for Paracetamol. It makes the drug’s API and finished dosage, the ready-for-consumption product.
Rival Glenmark Life Sciences is also expected to report its third-quarter results on Tuesday.
Read also: Granules India bags USFDA nod for Pantoprazole Sodium Delayed Release Tablets
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751